Navigation Links
Viking Therapeutics to Present at Upcoming Life Science Industry Events
Date:11/12/2015

SAN DIEGO, Nov. 12, 2015 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver corporate presentations at two upcoming life science industry events. Details for these presentations are as follows:

  • Stifel Healthcare Conference 2015 – webcast available
    Time/Date:  2:15 – 2:55 p.m. ET on Tuesday, November 17, 2015
    Location:  The New York Palace Hotel, New York City
  • Ligand Pharmaceuticals Analyst Day  – webcast available
    Time/Date:  10:00 – 11:30 a.m. ET on Wednesday, November 18, 2015
    Location:  Le Parker Meridien Hotel, New York City

To access the live webcast of Viking's presentation at the Stifel conference, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.

The Ligand analyst day will be webcast live and can be accessed at www.ligand.com.  A replay of this webcast will be available for 90 days following the event.

About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.  The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.  The company's clinical programs include VK5211, an orally available, non-steroidal SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist entering Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes.  Viking is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.

Learn more at: www.vikingtherapeutics.com.

Forward Looking Statements
This press release contains forward-looking statements regarding Viking Therapeutics, including statements about Viking's research and development activities. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials; and risks regarding regulatory requirements, among others. These forward-looking statements speak only as of the date hereof.  Viking disclaims any obligation to update these forward-looking statements.

 


'/>"/>
SOURCE Viking Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Viking Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update
2. Myelofibrosis Pipeline Therapeutics Reviewed for H2 2015 in New Research
3. Tobira Therapeutics Reports Third Quarter 2015 Financial Results
4. Astellas to Acquire Ocata Therapeutics
5. PTC Therapeutics Reports Third Quarter 2015 Financial Results, Provides Corporate Update and Reviews Key Findings from ACT DMD
6. UChicago and Evelo Therapeutics Partner to Advance Microbiome-based Cancer Immunotherapy
7. Therabron Therapeutics Receives Accelerated Second Tranche from Series B Financing and Expands Investor Syndicate
8. Clinical Data Featuring Trovagenes Precision Cancer Monitoring Platform to be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update
10. Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022 - Reportlinker Review
11. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2019)... ... , ... The 12-Step fellowship, Nicotine Anonymous (NicA), has grown ... in 32 countries. At meetings members share their experience with a process of ... and internet meetings. This expands the means by which members can connect, especially ...
(Date:12/6/2019)... , ... December 06, 2019 , ... ... to announce an expansion in services. While Kindred Nutrition and Wellness will ... counseling they are now happy to offer Individual and Family Therapy and Yoga. ...
(Date:12/5/2019)... ... 05, 2019 , ... Intelligent.com, a trusted resource for online ... Degree Programs for 2020. The comprehensive research guide is based on an assessment ... based on curriculum quality, graduation rate, reputation, and post-graduate employment. , The ...
Breaking Medicine Technology:
(Date:12/6/2019)... (PRWEB) , ... December 06, 2019 , ... TIME ... of 2019, spotlighting a mix of educational, innovative, and fun destinations that are tailored ... one of the 50 coolest places. , To assemble the list, TIME for Kids ...
(Date:12/5/2019)... ... 2019 , ... Abide, the #1 Christian meditation and sleep app, has helped ... bedtime stories. Listeners have recovered from bad dreams and night terrors, quit using sleeping ... one third of Americans suffer from poor sleep, which is linked to diabetes, obesity ...
(Date:12/5/2019)... ... December 05, 2019 , ... It’s ... launching exceptional products that help people embrace, achieve, and maintain a healthy lifestyle ... been more committed to our mission of impacting world health, so it’s gratifying ...
(Date:12/4/2019)... ... December 04, 2019 , ... Now ... provides protection from disruptions to cells and tissue and inflammation that leads to ... Lag, is available in a dietary supplement product called Prepair™ . , ...
(Date:12/4/2019)... ... December 04, 2019 , ... While the holidays are a time ... stress, said Texas A&M AgriLife Extension Service specialists. , “There are ... and benefit your overall wellness,” said Joyce Cavanagh, AgriLife Extension specialist in family economics, ...
Breaking Medicine News(10 mins):